Adenosine A2a receptor antagonists attenuate striatal adaptations following dopamine depletion

► A2a receptor antagonist treatment in a Parkinson's disease (PD) model. ► Attenuated PD related motor deficits. ► Prevented aberrant strengthening of corticostriatal synapses. ► Prevented aberrant alterations in spine morphology.